Olmesartan/Hidroclorotiazida Alter (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan/hydrochlorothiazide is used to manage hypertension by blocking the renin‑angiotensin system and promoting diuresis.

• Essential hypertension: lowers systolic and diastolic blood pressure to target levels.
• Hypertension in patients with renal impairment: provides effective blood pressure control when monotherapy is insufficient.
• Hypertension requiring combination therapy: offers dual action of an ARB and a thiazide diuretic for better control.

• Olmesartan medoxomil is converted to olmesartan, which selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, increasing urinary excretion of sodium and water. The combined effect reduces peripheral vascular resistance and plasma volume, leading to a sustained decrease in blood pressure.

Common side effects are generally mild and related to the pharmacologic actions of the components.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Increased urination: due to the diuretic effect of hydrochlorothiazide.
• Electrolyte imbalance (low potassium): may cause muscle cramps or weakness.
• Fatigue: occasional tiredness during dose titration.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Acute renal failure: sudden loss of kidney function, especially in volume‑depleted patients.
• Hyperkalemia: elevated potassium levels when combined with potassium‑sparing agents.
• Angioedema: swelling of face, lips, or throat requiring emergency care.
• Pancreatitis: inflammation of the pancreas, presenting with abdominal pain.
• Blood dyscrasias: rare blood cell abnormalities such as agranulocytosis.

Before initiating therapy, clinicians should assess patient-specific factors and monitor relevant parameters.

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Electrolyte and renal function tests: check serum potassium, sodium, creatinine, and eGFR regularly.
• Pregnancy and lactation: avoid use unless clearly needed, as safety data are limited.
• Concomitant potassium‑sparing drugs: use with caution to prevent hyperkalemia.
• Severe hepatic impairment: dose adjustment may be required.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/hydrochlorothiazide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Lithium: may increase lithium levels, risking toxicity.
• Potassium‑sparing diuretics (e.g., spironolactone): risk of hyperkalemia.
• ACE inhibitors or other ARBs: additive effect on potassium and renal function.
• NSAIDs (especially ibuprofen): may blunt antihypertensive response and affect renal function.
• Cyclosporine: can increase serum creatinine.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents: blood glucose may improve, requiring dose adjustment.
• Beta‑blockers: additive blood pressure lowering effect.
• Calcium channel blockers: may enhance hypotensive effect.
• Corticosteroids: can increase sodium retention, counteracting diuretic action.
• Digoxin: monitor serum levels due to potential electrolyte shifts.